Iovance Biotherapeutics (IOVA) Revenue (2023 - 2026)

Iovance Biotherapeutics (IOVA) has reported Revenue for 4 consecutive years, with $71.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 44.82% year-over-year to $71.4 million; the TTM figure through Mar 2026 stood at $285.6 million (up 34.29% YoY), while the FY2025 annual figure was $263.5 million, up 60.6% from the prior year.
• Revenue declined to $71.4 million in Q1 2026 per IOVA's latest filing, from $86.8 million in the prior quarter.
• Across five years, Revenue topped out at $86.8 million in Q4 2025 and bottomed at $238000.0 in Q2 2023.
• Historically, Revenue has averaged $41.7 million across 4 years, with a median of $53.9 million in 2024.
• Annual changes were most pronounced in 2024 — Revenue jumped 15189.21% — and 2025, when it climbed 15.2%.
• Iovance Biotherapeutics' Revenue stood at $482000.0 in 2023, then surged by 15189.21% to $73.7 million in 2024, then grew by 17.74% to $86.8 million in 2025, then declined by 17.68% to $71.4 million in 2026.
• Business Quant data shows IOVA's Revenue at $71.4 million in Q1 2026, $86.8 million in Q4 2025, and $67.5 million in Q3 2025.